An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis.

Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
Neuroscience Letters (Impact Factor: 2.06). 06/2009; 455(2):120-3. DOI: 10.1016/j.neulet.2009.02.048
Source: PubMed

ABSTRACT Methamphetamine continues to be the most widely abused drug in Japan. Chronic methamphetamine users show psychiatric signs, including methamphetamine psychosis. Monoamine oxidase A (MAOA) is one of the major enzymes responsible for the degradation of neurotransmitters. Abnormalities in MAO levels have been related to a wide range of psychiatric disorders. We examined whether or not the MAOA-u variable-number tandem repeat (VNTR) has a functional polymorphism in methamphetamine psychosis and whether or not such a polymorphism is related to the prolongation of psychosis. As expected, there was a significant difference in the MAOA-u VNTR between males with persistent versus transient methamphetamine psychosis (p=0.018, odds ratio (OR)=2.76, 95% CI: 1.18-6.46). Our results suggest that the high-activity allele class of MAOA-u VNTR in males may be involved in susceptibility to a persistent course of methamphetamine psychosis. We found no differences among females. The sample size of females with methamphetamine psychosis was too small to have significant analysis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g. neuroleptics), and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. In this chapter, we will provide an introduction to the typical clinical features and course of MAP as well as a review and discussion of the current putative genetic biomarkers for MAP. We will conclude with a discussion of the future directions and application of the MAP model with specific focus on how it may serve to elucidate further the complex neuromechanisms and discovery of viable biomarkers of SCZ. KeywordsMethamphetamine-Model of psychosis-Genetic-Biomarkers
    06/2011: pages 327-343;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Individuals vary in their responses to stimulant drugs, and several lines of evidence suggest that the basis for this variation is at least partially genetic in origin. Association studies have examined the effects of polymorphisms in specific genes on acute and chronic responses to stimulant drugs. Several of these genetic polymorphisms are also associated with other psychiatric dimensions and disorders. This chapter examines the evidence for genetic associations between the genes that have been most carefully examined for their influence on the response to stimulant drugs.
    Current topics in behavioral neurosciences. 01/2012;
  • [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the association of monoamine oxidase A- variable number of tandem repeat (MAOA-pVNTR) with susceptibility to Tourette's syndrome (TS) in Chinese Han population we discuss the genetic contribution of MAOA-VNTR in 141 TS patients including all their parents in Chinese Han population using transmission disequilibrium test (TDT) design. Our results revealed that no significant association was found in the MAOA gene promoter VNTR polymorphism and TS in Chinese Han population (TDT = 1.515, df = 1, p > 0.05). The negative result may be mainly due to the small sample size, but we don't deny the role of gene coding serotonergic or monoaminergic structures in the etiology of TS.
    Neurocase 01/2014; · 1.38 Impact Factor